PMID- 18156990
OWN - NLM
STAT- MEDLINE
DCOM- 20080215
LR  - 20200930
IS  - 1525-4135 (Print)
IS  - 1525-4135 (Linking)
VI  - 47
IP  - 1
DP  - 2008 Jan 1
TI  - Effect of baseline CD4 cell count on the efficacy and safety of peginterferon 
      Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
PG  - 36-49
AB  - OBJECTIVE: The impact of baseline CD4 status on hepatitis C virus (HCV) treatment 
      response among patients with HIV/HCV coinfection was investigated using data from 
      a randomized study of peginterferon alfa-2a (40KD) + ribavirin (Peg-IFN/RBV). 
      METHODS: Of 860 patients treated with conventional interferon alfa-2a + ribavirin 
      (IFN/RBV), peginterferon alfa-2a (40KD) + placebo (Peg-IFN), or Peg-IFN/RBV for 
      48 weeks, 857 patients had baseline CD4 data available and were included in the 
      analysis. Efficacy and safety were analyzed according to baseline CD4 status as 
      absolute cell count and proportion of total lymphocytes. RESULTS: Sustained 
      virologic response (SVR) rates were highest with Peg-IFN/RBV across all CD4 
      strata. With Peg-IFN/RBV, SVR rates were independent of baseline CD4 in genotype 
      2/3 patients, but in genotype 1 patients, they tended to be higher with higher 
      CD4 or CD4%. Frequencies of adverse events (AEs) and serious AEs were similar 
      among treatment arms and CD4 strata. Withdrawal and dose reduction rates 
      attributable to safety were highest with CD4 <200 cells/muL. CONCLUSIONS: 
      Peg-IFN/RBV could be effective and well tolerated in HIV/HCV-coinfected 
      individuals with stable HIV. With Peg-IFN/RBV, response tended to increase with 
      higher CD4 counts in genotype 1; however, because of the paucity of patients with 
      CD4 <200 cells/muL, these data require corroboration.
FAU - Opravil, Milos
AU  - Opravil M
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, Zurich, Switzerland. milos.opravil@usz.ch
FAU - Sasadeusz, Joe
AU  - Sasadeusz J
FAU - Cooper, David A
AU  - Cooper DA
FAU - Rockstroh, Jurgen K
AU  - Rockstroh JK
FAU - Clumeck, Nathan
AU  - Clumeck N
FAU - Clotet, Bonaventura
AU  - Clotet B
FAU - Montaner, Julio
AU  - Montaner J
FAU - Torriani, Francesca J
AU  - Torriani FJ
FAU - Depamphilis, Jean
AU  - Depamphilis J
FAU - Dieterich, Douglas T
AU  - Dieterich DT
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Placebos)
RN  - 0 (RNA, Viral)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Antiviral Agents/administration & dosage/adverse effects/*therapeutic use
MH  - *CD4 Lymphocyte Count
MH  - Genotype
MH  - HIV/genetics/isolation & purification
MH  - HIV Infections/*complications/immunology
MH  - Hepacivirus/genetics/isolation & purification
MH  - Hepatitis C/*drug therapy/immunology
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/administration & dosage/adverse effects/*therapeutic use
MH  - Placebos
MH  - Polyethylene Glycols/administration & dosage/adverse effects/*therapeutic use
MH  - RNA, Viral/genetics
MH  - Recombinant Proteins
MH  - Ribavirin/administration & dosage/adverse effects/*therapeutic use
MH  - Viral Load
EDAT- 2007/12/25 09:00
MHDA- 2008/02/19 09:00
CRDT- 2007/12/25 09:00
PHST- 2007/12/25 09:00 [pubmed]
PHST- 2008/02/19 09:00 [medline]
PHST- 2007/12/25 09:00 [entrez]
AID - 00126334-200801010-00004 [pii]
AID - 10.1097/QAI.0b013e31815ac47d [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):36-49. doi: 
      10.1097/QAI.0b013e31815ac47d.